Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 675 participants.
Also called NCT01098981
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 675 participants
- Sponsor
- Cerevast Therapeutics, Inc.
- Registry
-
NCT01098981
-
- Other papers using this trial's data
- Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial
- Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT01098981. Randomized; triple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
- Acronym
- CLOTBUST-ER
- Condition
- Acute Ischemic Stroke
- Intervention (Device)
- Transcranial ultrasound as an adjunctive therapy to tPA
- Intervention (Drug)
- Standard of care tPA therapy for acute ischemic stroke
- Lead sponsor
- Cerevast Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct01098981- Content hash
cbdee610c22b0c58ee2777f8cc50420278354cb5bcec68222034649328514690